Related references
Note: Only part of the references are listed.Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension
Marc Humbert et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2022)
Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombus: A Systematic Review and Meta-analysis
Cameron Burmeister et al.
AMERICAN JOURNAL OF THERAPEUTICS (2021)
Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
Ke-Xin Sun et al.
FRONTIERS IN PHARMACOLOGY (2021)
Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis
Mohammed Mhanna et al.
AMERICAN JOURNAL OF THERAPEUTICS (2021)
A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension
Katherine Bunclark et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study
Sert Sena et al.
PULMONARY CIRCULATION (2020)
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
N. van Es et al.
BLOOD (2014)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)